EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 improved liver function and uric acid management-A pilot study

Jia-Hung Lin, Chi-Huei Lin, Yi-Wei Kuo, Chorng-An Liao iD, Jui-Fen Chen, Shin-Yu Tsai, Ching-Min Li, Yu-Chieh Hsu, Yen-Yu Huang iD, Ko-Chiang Hsia, Yao-Tsung Yeh iD, Hsieh-Hsun Ho iD

PLOS ONE · 24.07.2024 · 19 (7) · e0307181

DOI: 10.1371/journal.pone.0307181 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, online erschienen am 24.07.2024. Verfasst von Jia-Hung Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Functional R&D Department, Research and Design Center, Glac Biotech Co., Ltd., Tainan City, Taiwan. Hauptthemen laut MEDLINE: Probiotics, Limosilactobacillus reuteri, Lactiplantibacillus plantarum, Limosilactobacillus fermentum. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Glac Biotech Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic-associated fatty liver disease (MAFLD) is predominantly associated with metabolic disturbances representing aberrant liver function and increased uric acid (UA) levels. Growing evidences have suggested a close relationship between metabolic disturbances and the gut microbiota. A placebo-controlled, double-blinded, randomized clinical trial was therefore conducted to explore the impacts of daily supplements with various combinations of the probiotics, Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 with a focus on liver function and serum UA levels. Test subjects with abnormal levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and UA were recruited and randomly allocated into six groups. Eighty-two participants successfully completed the 60-day intervention without any dropouts or occurrence of adverse events. The serum AST, ALT, and UA levels were significantly reduced in all treatment groups ( P < 0.05). The fecal microbiota analysis revealed the intervention led to an increase in the population of commensal bacteria and a decrease in pathobiont bacteria, especially Bilophila wadsworthia . The in vitro study indicated the probiotic treatments reduced lipid accumulation and inflammatory factor expressions in HepG2 cells, and also promoted UA excretion in Caco-2 cells. The supplementation of multi-strain probiotics (TSF331, TSR332, and TSP05) together can improve liver function and UA management and may have good potential in treating asymptomatic MAFLD. Trial registration . The trial was registered in the US Library of Medicine (clinicaltrials.gov) with the number NCT06183801 on December 28, 2023.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsLimosilactobacillus reuteriLactiplantibacillus plantarumLimosilactobacillus fermentumUric AcidHumansMaleFemalePilot ProjectsMiddle AgedDouble-Blind MethodLiverAdultGastrointestinal MicrobiomeHep G2 CellsCaco-2 CellsAspartate AminotransferasesFecesAlanine Transaminase

Substanzen

Uric AcidAspartate AminotransferasesAlanine Transaminase

Autor:innen und Institutionen

  • Functional R&D Department, Research and Design Center, Glac Biotech Co., Ltd., Tainan City, Taiwan.
  • Aging and Disease Prevention Research Center, Fooyin University, Kaohsiung City, Taiwan.
  • Research Product Department, Research and Design Center, Glac Biotech Co., Ltd., Tainan City, Taiwan.
  • Department of Medical Laboratory Sciences and Biotechnology, Fooyin University, Kaohsiung City, Taiwan.

ORCID-Profile: Chorng-An Liao, Yen-Yu Huang, Yao-Tsung Yeh, Hsieh-Hsun Ho

Förderung

  • Glac Biotech Co., Ltd.

Zitieren

APA

Lin, J. H., Lin, C. H., Kuo, Y. W., Liao, C. A., Chen, J. F., Tsai, S. Y., Li, C. M., Hsu, Y. C., Huang, Y. Y., Hsia, K. C., Yeh, Y. T., & Ho, H. H. (2024). Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 improved liver function and uric acid management-A pilot study. PLOS ONE, 19(7), e0307181. https://doi.org/10.1371/journal.pone.0307181

Vancouver

Lin JH, Lin CH, Kuo YW, Liao CA, Chen JF, Tsai SY, et al. Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 improved liver function and uric acid management-A pilot study. PLOS ONE. 2024;19(7):e0307181. doi:10.1371/journal.pone.0307181

BibTeX
@article{Lin2024,
  author = {Lin, Jia-Hung and Lin, Chi-Huei and Kuo, Yi-Wei and Liao, Chorng-An and Chen, Jui-Fen and Tsai, Shin-Yu and Li, Ching-Min and Hsu, Yu-Chieh and Huang, Yen-Yu and Hsia, Ko-Chiang and Yeh, Yao-Tsung and Ho, Hsieh-Hsun},
  title = {Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 improved liver function and uric acid management-A pilot study},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {7},
  pages = {e0307181},
  doi = {10.1371/journal.pone.0307181}
}
Kostenlos starten →